CA3126959A1 - Cancer treatment - Google Patents
Cancer treatment Download PDFInfo
- Publication number
- CA3126959A1 CA3126959A1 CA3126959A CA3126959A CA3126959A1 CA 3126959 A1 CA3126959 A1 CA 3126959A1 CA 3126959 A CA3126959 A CA 3126959A CA 3126959 A CA3126959 A CA 3126959A CA 3126959 A1 CA3126959 A1 CA 3126959A1
- Authority
- CA
- Canada
- Prior art keywords
- erdafitinib
- treatment
- cancer
- daily
- serum phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 442
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 300
- 201000011510 cancer Diseases 0.000 title claims abstract description 281
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 claims abstract description 590
- 229950004444 erdafitinib Drugs 0.000 claims abstract description 589
- 238000000034 method Methods 0.000 claims abstract description 87
- 229910019142 PO4 Inorganic materials 0.000 claims description 366
- 239000010452 phosphate Substances 0.000 claims description 366
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 365
- 210000002966 serum Anatomy 0.000 claims description 355
- 239000003814 drug Substances 0.000 claims description 102
- 108091008794 FGF receptors Proteins 0.000 claims description 70
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 69
- 230000001394 metastastic effect Effects 0.000 claims description 43
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 43
- 238000004519 manufacturing process Methods 0.000 claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 230000009278 visceral effect Effects 0.000 claims description 36
- 206010027476 Metastases Diseases 0.000 claims description 35
- 230000004077 genetic alteration Effects 0.000 claims description 27
- 231100000118 genetic alteration Toxicity 0.000 claims description 27
- 230000005945 translocation Effects 0.000 claims description 26
- 230000035772 mutation Effects 0.000 claims description 24
- 102000001554 Hemoglobins Human genes 0.000 claims description 20
- 108010054147 Hemoglobins Proteins 0.000 claims description 20
- 210000004185 liver Anatomy 0.000 claims description 13
- 210000000988 bone and bone Anatomy 0.000 claims description 12
- 210000004072 lung Anatomy 0.000 claims description 12
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims 12
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 230000002354 daily effect Effects 0.000 description 295
- 231100000419 toxicity Toxicity 0.000 description 64
- 230000001988 toxicity Effects 0.000 description 64
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 58
- 230000004044 response Effects 0.000 description 57
- 239000002694 phosphate binding agent Substances 0.000 description 32
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 31
- 229960003693 sevelamer Drugs 0.000 description 31
- 230000009467 reduction Effects 0.000 description 20
- 238000002512 chemotherapy Methods 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 17
- 230000004927 fusion Effects 0.000 description 13
- 230000002411 adverse Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000012453 solvate Substances 0.000 description 11
- 206010061818 Disease progression Diseases 0.000 description 10
- 230000005750 disease progression Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 230000037442 genomic alteration Effects 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
- 229960004316 cisplatin Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 6
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 6
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 6
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 6
- 201000005991 hyperphosphatemia Diseases 0.000 description 6
- 208000033379 Chorioretinopathy Diseases 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000037336 dry skin Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011521 systemic chemotherapy Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 208000023747 urothelial carcinoma Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101000836150 Homo sapiens Transforming acidic coiled-coil-containing protein 3 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010059206 Nail toxicity Diseases 0.000 description 3
- 206010038848 Retinal detachment Diseases 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 102100027048 Transforming acidic coiled-coil-containing protein 3 Human genes 0.000 description 3
- 238000011226 adjuvant chemotherapy Methods 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 231100000465 nail toxicity Toxicity 0.000 description 3
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 231100000683 possible toxicity Toxicity 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 208000003265 stomatitis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 101150081124 FGFR gene Proteins 0.000 description 2
- 101150025764 FGFR3 gene Proteins 0.000 description 2
- 230000010558 Gene Alterations Effects 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000007684 eye toxicity Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100000327 ocular toxicity Toxicity 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 231100000857 poor renal function Toxicity 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 102200143272 rs121913479 Human genes 0.000 description 2
- 102200143269 rs121913482 Human genes 0.000 description 2
- 102200143266 rs121913483 Human genes 0.000 description 2
- 102200143271 rs121913485 Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000037911 visceral disease Diseases 0.000 description 2
- 102100024387 AF4/FMR2 family member 3 Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004251 Ammonium lactate Substances 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100028265 Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 102100031048 Coiled-coil domain-containing protein 6 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000833166 Homo sapiens AF4/FMR2 family member 3 Proteins 0.000 description 1
- 101000935886 Homo sapiens Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 Proteins 0.000 description 1
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 description 1
- 101000777370 Homo sapiens Coiled-coil domain-containing protein 6 Proteins 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 206010028698 Nail dystrophy Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000006187 Onycholysis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 206010033553 Palmar-plantar erythrodysaesthesia syndrome Diseases 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038886 Retinal oedema Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940059265 ammonium lactate Drugs 0.000 description 1
- 235000019286 ammonium lactate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- -1 cyclodextrins Chemical class 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 239000012437 perfumed product Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 201000011195 retinal edema Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000009528 vital sign measurement Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19156806.2 | 2019-02-12 | ||
| EP19156806 | 2019-02-12 | ||
| EP19176575 | 2019-05-24 | ||
| EP19176575.9 | 2019-05-24 | ||
| PCT/EP2020/053490 WO2020165181A1 (en) | 2019-02-12 | 2020-02-11 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3126959A1 true CA3126959A1 (en) | 2020-08-20 |
Family
ID=69467563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3126959A Pending CA3126959A1 (en) | 2019-02-12 | 2020-02-11 | Cancer treatment |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220168298A1 (enExample) |
| EP (1) | EP3923942A1 (enExample) |
| JP (1) | JP2022521173A (enExample) |
| KR (1) | KR20210126654A (enExample) |
| CN (1) | CN113423402A (enExample) |
| AU (1) | AU2020223467B2 (enExample) |
| BR (1) | BR112021015686A2 (enExample) |
| CA (1) | CA3126959A1 (enExample) |
| IL (1) | IL285466A (enExample) |
| JO (1) | JOP20210216A1 (enExample) |
| MA (1) | MA54932A (enExample) |
| MX (1) | MX2021009670A (enExample) |
| PH (1) | PH12021551949A1 (enExample) |
| SG (1) | SG11202107850VA (enExample) |
| TW (1) | TWI863962B (enExample) |
| WO (1) | WO2020165181A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4259638A4 (en) * | 2020-12-11 | 2024-10-23 | Erasca, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| CN117083283A (zh) * | 2020-12-11 | 2023-11-17 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| CN112957368A (zh) * | 2021-04-02 | 2021-06-15 | 南昌大学 | 一种司维拉姆的新用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037920B1 (ru) * | 2014-09-26 | 2021-06-07 | Янссен Фармацевтика Нв | Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr |
| JOP20200201A1 (ar) * | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| MX382526B (es) * | 2015-10-23 | 2025-03-13 | Array Biopharma Inc | Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr |
| JOP20190190A1 (ar) * | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
| TWI798199B (zh) * | 2017-02-06 | 2023-04-11 | 比利時商健生藥品公司 | 癌症治療 |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
-
2020
- 2020-02-11 KR KR1020217028671A patent/KR20210126654A/ko active Pending
- 2020-02-11 PH PH1/2021/551949A patent/PH12021551949A1/en unknown
- 2020-02-11 WO PCT/EP2020/053490 patent/WO2020165181A1/en not_active Ceased
- 2020-02-11 CN CN202080013784.5A patent/CN113423402A/zh active Pending
- 2020-02-11 SG SG11202107850VA patent/SG11202107850VA/en unknown
- 2020-02-11 AU AU2020223467A patent/AU2020223467B2/en active Active
- 2020-02-11 US US17/430,025 patent/US20220168298A1/en active Pending
- 2020-02-11 JP JP2021547154A patent/JP2022521173A/ja not_active Withdrawn
- 2020-02-11 MX MX2021009670A patent/MX2021009670A/es unknown
- 2020-02-11 BR BR112021015686-0A patent/BR112021015686A2/pt unknown
- 2020-02-11 CA CA3126959A patent/CA3126959A1/en active Pending
- 2020-02-11 JO JOP/2021/0216A patent/JOP20210216A1/ar unknown
- 2020-02-11 EP EP20703477.8A patent/EP3923942A1/en active Pending
- 2020-02-11 MA MA054932A patent/MA54932A/fr unknown
- 2020-02-12 TW TW109104389A patent/TWI863962B/zh active
-
2021
- 2021-08-09 IL IL285466A patent/IL285466A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20210216A1 (ar) | 2023-01-30 |
| BR112021015686A2 (pt) | 2021-10-26 |
| MX2021009670A (es) | 2021-09-08 |
| SG11202107850VA (en) | 2021-08-30 |
| KR20210126654A (ko) | 2021-10-20 |
| MA54932A (fr) | 2021-12-22 |
| JP2022521173A (ja) | 2022-04-06 |
| TW202045173A (zh) | 2020-12-16 |
| US20220168298A1 (en) | 2022-06-02 |
| AU2020223467A1 (en) | 2021-08-05 |
| WO2020165181A1 (en) | 2020-08-20 |
| TWI863962B (zh) | 2024-12-01 |
| IL285466A (en) | 2021-09-30 |
| EP3923942A1 (en) | 2021-12-22 |
| AU2020223467B2 (en) | 2025-12-04 |
| CN113423402A (zh) | 2021-09-21 |
| PH12021551949A1 (en) | 2022-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3576740B1 (en) | Cancer treatment | |
| WO2018141921A1 (en) | Cancer treatment | |
| AU2018278271A1 (en) | FGFR2 inhibitors for the treatment of cholangiocarcinoma | |
| AU2020223467B2 (en) | Cancer treatment | |
| EP4548935A2 (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| HK40103983A (en) | Cancer treatment | |
| HK40018978A (en) | Cancer treatment | |
| HK40018978B (en) | Cancer treatment | |
| EP3946341A1 (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| AU2020253054B2 (en) | FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| HK40013982A (en) | Cancer treatment | |
| JP2025511352A (ja) | がんの処置のためのｇｄｃ－６０３６およびｇｄｃ－００７７を含む併用療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| EEER | Examination request |
Effective date: 20220928 |
|
| EEER | Examination request |
Effective date: 20220928 |
|
| EEER | Examination request |
Effective date: 20220928 |